Evidence map›Paper›PMID 28841362›Full record

ReviewHuman vaccines & immunotherapeutics2017

Use of the live attenuated Japanese Encephalitis vaccine SA 14-14-2 in children: A review of safety and tolerability studies.

Amy Sarah Ginsburg, Ankita Meghani, Scott B Halstead, Mansour Yaich

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Safety of Japanese encephalitis vaccines.Human vaccines & immunotherapeutics · 2021
    Article
  7. Article
  8. Hospital-based surveillance for Japanese encephalitis in Bangladesh, 2007-2016: Implications for introduction of immunization.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020
    Article
  9. Review
  10. Japanese Encephalitis Vaccines.Current treatment options in infectious diseases · 2020
    Review
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Amy Sarah Ginsburga Save the Children , Seattle , WA , USA.
Ankita Meghanib Department of International Health , Johns Hopkins Bloomberg School of Public Health , Baltimore , MD , USA.
Scott B Halsteadc Department of Preventive Medicine and Biometrics , Uniformed Services University of the Health Sciences , Bethesda , MD , USA.
Mansour Yaichd Vaxyn Consulting , Paris , France.
Johns Hopkins University · USSave the Children · USUniformed Services University of the Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Japanese encephalitis (JE) is the leading cause of viral neurological disease and disability in Asia. Some 50-80% of children with clinical JE die or have long-term neurologic sequelae. Since there is no cure, human vaccination is the only effective long-term control measure, and the World Health Organization recommends that at-risk populations receive a safe and effective vaccine. Four different types of JE vaccines are currently available: inactivated mouse brain-derived vaccines, inactivated Vero cell vaccines, live attenuated SA 14-14-2 vaccines and a live recombinant (chimeric) vaccine. With the rapidly increasing demand for and availability and use of JE vaccines, countries face an important decision in the selection of a JE vaccine. This article provides a comprehensive review of the available safety literature for the live attenuated SA 14-14-2 JE vaccine (LAJEV), the most widely used new generation JE vaccine. With well-established effectiveness data, a single dose of LAJEV protects against clinical JE disease for at least 5 years, providing a long duration of protection compared with inactivated mouse brain-derived vaccines. Since 1988, about 700 million doses of the LAJEV have been distributed globally. Our review found that LAJEV is well tolerated across a wide age range and can safely be given to children as young as 8 months of age. While serious adverse events attributable to LAJEV have been reported, independent experts have not found sufficient evidence for causality based on the available data.

Indexed as

AdolescentAsiaChildChild, PreschoolClinical Trials as TopicEncephalitis, JapaneseFemaleHumansInfantJapanese Encephalitis VaccinesMaleVaccinationVaccines, AttenuatedJapanese Encephalitis VaccinesSA-14-14-2 vaccineVaccines, Attenuatedadverse eventsJapanese encephalitislive attenuated SA 14–14–2 vaccineserious adverse eventsvaccine safety

Identifiers

PMID28841362
PMCPMC5647966
OpenAlexW2748771526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.